Professor, Chair of Anaesthesiology, The University of Western Australia, School of Medicine and Pharmacology, Pharmacology, Pharmacy and Anaesthesiology Unit , Perth , Australia.
Expert Opin Pharmacother. 2015 Jan;16(1):5-15. doi: 10.1517/14656566.2015.980723. Epub 2014 Dec 5.
Cancer pain is one of the most important symptoms of malignant disease, which has a major impact on the quality of life of cancer patients. Therefore, it needs to be treated appropriately after a careful assessment of the types and causes of pain.
The mainstay of cancer pain management is systemic pharmacotherapy. This is, in principle, still based on the WHO guidelines initially published in 1986. Although these have been validated, they are not evidence-based. The principles are a stepladder approach using non-opioids, weak and then strong opioids. In addition, adjuvants can be added at any step to address specific situations such as bone or neuropathic pain. Patients, even if they are on long-acting opioids, need to be provided with immediate-release opioids for breakthrough pain. In case of inefficacy or severe adverse effects of one opioid, rotation to another opioid is recommended.
There is a major need for more and better randomized controlled trials in the setting of cancer pain as the lack of evidence is hampering the improvement of current treatment guidelines.
癌痛是恶性肿瘤最重要的症状之一,严重影响癌症患者的生活质量。因此,在仔细评估疼痛的类型和原因后,需要对其进行适当的治疗。
癌症疼痛管理的主要方法是系统药物治疗。这原则上仍然基于 1986 年最初发布的世界卫生组织指南。虽然这些指南已经过验证,但它们不是基于证据的。原则是使用非阿片类药物、弱阿片类药物和强阿片类药物逐步治疗。此外,在任何阶段都可以添加辅助药物来解决特定情况,如骨痛或神经病理性疼痛。即使患者正在使用长效阿片类药物,也需要为爆发性疼痛提供即释阿片类药物。如果一种阿片类药物无效或出现严重不良反应,建议更换另一种阿片类药物。
在癌症疼痛的治疗中,需要进行更多和更好的随机对照试验,因为缺乏证据正在阻碍当前治疗指南的改进。